Alpha Omega Wealth Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Alpha Omega Wealth Management LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 30.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 179,570 shares of the biopharmaceutical company's stock after acquiring an additional 42,083 shares during the period. Alpha Omega Wealth Management LLC's holdings in Pfizer were worth $4,550,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of PFE. Norges Bank bought a new position in Pfizer during the fourth quarter worth about $2,328,986,000. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Starboard Value LP acquired a new position in Pfizer during the fourth quarter valued at approximately $407,730,000. Raymond James Financial Inc. bought a new position in shares of Pfizer in the fourth quarter valued at $274,694,000. Finally, Assenagon Asset Management S.A. grew its position in shares of Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.1%

Shares of NYSE:PFE traded up $0.28 during mid-day trading on Thursday, hitting $24.76. The company had a trading volume of 26,429,960 shares, compared to its average volume of 41,018,673. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $140.77 billion, a PE ratio of 17.56, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The firm has a fifty day moving average price of $22.96 and a 200 day moving average price of $24.98. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. During the same period in the previous year, the company posted $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 6.95%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

A number of research analysts recently weighed in on PFE shares. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.